Physician profile
Benjamin Brian Brannick
NPI 1679718357
$83,681.34
in general payments reported to CMS, 2019-2025
57 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $2,761 · 2021: $2,055 · 2022: $4,983 · 2023: $18K · 2024: $12K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $22K · Consulting Fee: $12K · Food and Beverage: $12K · Travel and Lodging: $5,756 · Education: $41.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $22,207.50 |
| Consulting Fee | $11,970.00 |
| Food and Beverage | $11,891.16 |
| Travel and Lodging | $5,755.95 |
| Education | $41.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $41,978.71 | 2020-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Sanofi-Aventis U.S. LLC | $19,059.68 | 2019-2025 | |
| Corcept Therapeutics | $2,773.71 | 2019-2025 | Korlym |
| Novo Nordisk INC | $2,718.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,930.88 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,593.29 | 2019-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,524.60 | 2019-2025 | Jardiance, Synjardy |
| Alexion Pharmaceuticals, INC. | $1,220.94 | 2019-2025 | Strensiq |
| Abbvie INC. | $1,093.11 | 2019-2025 | Lupron Depot, Synthroid |
| Astrazeneca Pharmaceuticals LP | $1,036.14 | 2019-2024 | Farxiga |
| Insulet Corporation | $882.19 | 2019-2024 | Omnipod |
| Medtronic Minimed, INC. | $789.57 | 2019-2020 | |
| Mannkind Corporation | $562.02 | 2019-2025 | Afrezza |
| Medtronic, INC. | $482.75 | 2021-2024 | Minimed 780g, Minimed 770g |
| Abbott Laboratories | $447.82 | 2019-2025 | Freestyle Libre, Eterna, Freestyle Libre 3 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $419.87 | 2021-2024 | |
| Dexcom, INC. | $377.23 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Antares Pharma, INC. | $372.77 | 2019-2025 | Xyosted |
| Sequel Med Tech, LLC | $371.48 | 2024-2025 | Twiist |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.83 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $292.35 | 2022-2025 | Yorvipath, Skytrofa |
| Beta Bionics, INC. | $287.82 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $254.12 | 2024-2025 | Cequr Simplicity |
| Kyowa Kirin, INC. | $228.86 | 2023-2025 | Crysvita |
| Horizon Therapeutics Plc | $226.90 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $223.71 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $189.25 | 2020-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $164.54 | 2020-2023 | Tirosint, Tirosint, Licart |
| Ascensia Diabetes Care US INC. | $164.14 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $161.41 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $146.29 | 2025 | |
| Merck Sharp & Dohme LLC | $137.64 | 2019-2021 | |
| Amryt Pharma Holdings LTD | $135.80 | 2023 | Mycapssa |
| Azurity Pharmaceuticals, INC. | $127.45 | 2022-2025 | Triptodur, Triptodur |
| Pfizer INC. | $105.41 | 2019-2025 | |
| Madrigal Pharmaceuticals | $100.24 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $98.04 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $92.59 | 2022-2024 | Senza |
| Radius Health, INC. | $89.27 | 2019-2025 | Tymlos |
| Arbor Pharmaceuticals, INC. | $53.89 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.77 | 2023-2024 | |
| Eusa Pharma (US) LLC | $39.31 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $37.48 | 2023-2024 | Imcivree, Imcivree |
| Amphastar Pharmaceuticals, INC. | $32.13 | 2025 | |
| Verity Pharmaceuticals INC. | $28.66 | 2025 | Tlando |
| Amneal Pharmaceuticals LLC | $27.40 | 2021-2025 | Unithroid |
| Shire North American Group INC | $27.16 | 2019 | |
| Biomarin Pharmaceutical INC. | $22.65 | 2023 | Voxzogo 1.2mg |
| Almatica Pharma LLC | $21.53 | 2025 | Teriparatide |
| Regeneron Healthcare Solutions, INC. | $19.85 | 2022 | |
| Astellas Pharma US INC | $19.44 | 2023 | Veozah |
| Soleno Therapeutics, INC. | $17.25 | 2025 | Vykat Xr |
| Endo USA, INC. | $16.75 | 2025 | Supprelin |
| Esteve Pharmaceuticals LLC | $15.67 | 2025 | Metopirone |
| Endo Pharmaceuticals INC. | $15.66 | 2019 | |
| Eisai INC. | $13.75 | 2023 | |
| Ferring Pharmaceuticals INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Brannick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.